Lori Anne Kunkel Sells Enliven Therapeutics Stock

On July 6, 2026, Lori Anne Kunkel, a director at Enliven Therapeutics, Inc. (ELVN), sold a total of 10,000 shares of common stock. The sales were executed under a Rule 10b5-1 trading plan. The first transaction involved 4,111 shares sold at a weighted average price of $49.98, resulting in 47,773 shares remaining. The second transaction involved 5,889 shares sold at a weighted average price of $50.84, leaving 41,884 shares. These transactions were part of a series of sales conducted at prices ranging from $49.40 to $51.38.